Clinical trial
A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing…
NCT00298038 · Bausch Health Americas, Inc., Industry · Completed
Key facts
| NCT number | NCT00298038 |
|---|---|
| Title | A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy |
| Official title | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy |
| Lead sponsor | Bausch Health Americas, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatic Encephalopathy |
| Intervention type | Drug |
| Interventions | Rifaximin, Placebo |
| Enrollment | 299 |
| Start date | Dec 19, 2005 |
| Primary completion | Aug 15, 2008 |
| Completion | Aug 15, 2008 |
| First posted | Mar 1, 2006 |
| Last update posted | Sep 18, 2019 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: